AstraZeneca increases drug stockpile in preparation for no-deal Brexit

pharmafile | July 18, 2018 | News story | Research and Development AstraZeneca, brexit, no-deal, pharma, stockpiling 

The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the European Union in preparation for a hard, no-deal Brexit.

The Vice President of AstraZeneca’s Global External Manufacturing, Juliette White, told BBC’s Newsnight that:  “Ultimately – and as a safety net – we will increase the amount of finished medicines available to pharmacies and hospitals in those countries [referring to both the UK and those countries inside the EU]. We always have an additional amount of medicines available. We are increasing that by about 20%.”

White stated that the multinational pharmaceutical firm had been preparing for a no-deal Brexit since 2016. Pascal Soirot, the company’s CEO, called for clarity in regards to Brexit last year, saying that: “What is starting to worry me, I must say, is the potential for the one thing I didn’t think would happen, which is a hard Brexit. If there is no extension we will be left in limbo because the UK will come out of Europe and we will have no trade agreements.”

AstraZeneca have already spent £40 million in preparation for a no-deal Brexit. The company, who currently employ 7,000 people in the UK, has a team of 30 who are tasked with preparing for Britain’s exit from the European Union.

A no-deal arrangement would halt the free flow of drugs between Britain and the EU. While 45 million packs of medicine are imported into Europe from the UK, 37 million packs are transported in the other direction. Although EU regulations currently allow for the movement of drugs between countries in the EU, in the case of a no-deal Brexit, drugs would have to be tested and registered in both the UK and EU in order to be legally valid in both regions.

The statement comes as the EMA stated last week that it had identified gaps in the pharma industry’s preparedness for Brexit.

Louis Goss

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content